Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 426-429

  Davies, M J ^a   Trujillo, A ^a   Vijapurkar, U ^a   Damaraju, C V ^a   Meininger, G ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Diabetes complications; Drug mechanism; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO; SULFONYLUREA; URIC ACID; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERURICEMIA; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOWN REGULATION; KIDNEY CALCULI; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK;

ADULT; AGED; CANAGLIFLOZIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GOUT; HUMANS; HYPERURICEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY CALCULI; MALE; MIDDLE AGED; RISK; SODIUM-GLUCOSE TRANSPORTER 2; URIC ACID;

EID: 84924677348     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12439     Document Type: Letter

References (14)

1. Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2012; 15: 372-382.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495-502.
3. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 2014; 126: 16-34.
4. Becker M, Roessler BJ. Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th edn. New York: McGraw-Hill, 1995; 1655-1677.
5. Ito H, Abe M, Mifune M et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One 2011; 6: e27817.
6. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 2012; 176: 108-116.
7. Xu Y, Zhu J, Gao L et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One 2013; 8: e78206.
8. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515.
9. Lavalle-González FJ, Januszewicz A, Davidson J etal. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia 2013; 56: 2582-2592.
10. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477.
11. Reinders MK, Jansen TL. Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 2010; 5: 7-18.
12. Sha S, Polidori D, Heise T et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 1087-1095.
13. Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
14. Chino Y, Samukawa Y, Sakai S et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391-404.